Microwave ablation guided by ultrasound for symptomatic uterine fibroids
Tests microwave heat treatment that keeps the uterus, in women with symptomatic fibroids.
Key facts
- Who runs it
- Jihad Hussien Mohamed Mahmoud
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy of Ultrasound Guided Microwave Ablation in the Treatment of Uterine Fibroids.
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- 30 Nov 2025
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Ultrasound-Guided Percutaneous Microwave Thermal Ablation
- Record updated
- 19 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who have not gone through menopause and have uterine fibroids that cause symptoms. They will be treated with microwave heat guided by ultrasound.
- Age
- 25 years or older
- Sex
- Women only
- Disease stage
- Uterine fibroids that cause symptoms. Fewer than 5 fibroids, each less than 10 cm (3.9 in). The examining gynecologist must judge that microwave treatment can be done. Women must be in good general health and able to have general anesthesia or sedation.
Main reasons for not taking part
- Taking blood thinners now, or a known bleeding disorder
- Long-term illness that makes general anesthesia unsafe, or poor general health
- Pregnancy
- Having gone through menopause
- 5 or more fibroids, or a fibroid 10 cm (3.9 in) or larger
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Female patients aged 25 years or older Good general health Symptomatic uterine fibroids suitable for microwave ablation as determined by examining gynecologist Premenopausal status Acceptable risks for general anesthesia or sedation Number of fibroids: fewer than 5 Size of fibroid: less than 10 cm
Who cannot take part
- Ongoing anticoagulant treatment and/or known bleeding disorder Chronic diseases contraindicating general anesthesia Pregnancy Postmenopausal status 5 or more fibroids Fibroid size 10 cm or larger Poor general health precluding anesthesia or sedation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Uterine fibroids are the most common benign tumors of the female genital tract and can significantly affect the quality of life in reproductive-age women, causing symptoms such as heavy menstrual bleeding, pelvic pressure, urinary disturbances, dyspareunia, and infertility. Traditional surgical interventions such as myomectomy and hysterectomy remain the standard of care, yet they are associated with considerable trauma, longer recovery times, and the loss of uterine function.
Read full original descriptionShow less
Microwave ablation (MWA) is a minimally invasive image-guided technique that uses microwave energy to induce coagulative necrosis in fibroid tissue, reducing its size and alleviating symptoms while preserving the uterus. This study aims to evaluate the feasibility, safety, and therapeutic effectiveness of ultrasound-guided percutaneous microwave thermal ablation (PMTA) in the management of symptomatic uterine fibroids.
Eligible participants are premenopausal women aged 25 years or older with symptomatic fibroids less than 10 cm in size and fewer than five in number. Exclusion criteria include pregnancy, bleeding disorders, chronic diseases contraindicating anesthesia, and ongoing anticoagulant therapy.
Each participant will undergo ultrasound-guided microwave ablation under aseptic conditions and sedation. Fibroid size, menstrual bleeding patterns, hemoglobin levels, and pain scores will be evaluated at baseline and during follow-up at 3 and 6 months. The primary outcome is the reduction in fibroid size, while secondary outcomes include symptom improvement and hemoglobin level changes.
This prospective case series will be conducted at Assiut University Hospitals, Egypt, with 20 participants referred from the Gynecology Department to the Interventional Radiology Unit. The results will provide valuable data on the clinical value of MWA as a uterus-preserving alternative for symptomatic uterine fibroids.
The group in the trial
- Microwave Ablation TreatmentTreatment being tested
Patients with symptomatic uterine fibroids who meet inclusion criteria will undergo ultrasound-guided percutaneous microwave thermal ablation (PMTA). The procedure involves percutaneous insertion of a microwave needle (1.4 to 1.6mm diameter and 15 to 20 cm length) into the fibroid under US guidance, with thermal ablation continuing for 10 to 30 minutes under IV sedation. Patients will be followed at 3 and 6 months to assess fibroid size reduction and symptom improvement.
Treatment: Ultrasound-Guided Percutaneous Microwave Thermal Ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Ultrasound Guided Microwave Ablation in the Treatment of Uterine Fibroids.
- Plain-language title
- Microwave ablation guided by ultrasound for symptomatic uterine fibroidsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 19 November 2025